When we started our project in 2012, we knew that only a highly advanced technological solution would be able to provide a solution to the challenges we wanted to accomplish. Furthermore, we were aware that there wasn’t already a solution on the market (and still there isn’t one) capable of sending out a warning signal before an epilepsy crisis. Only by investing to develop R&D in different areas: hardware design, artificial intelligence, mobile applications capable of integrating algorithms that work in real-time, and many other aspects, we would be able to respond to the problem of an epileptic seizure occurring without prior warning.

For a startup like us, only the involvement of different agents both from the public and private sectors makes it possible to obtain these resources. And although access to these funds is often highly competitive, without the help of these programs it would be impossible for projects like ours to become a reality that fulfills their function: to provide a response to people’s real problems.

For this reason, we would like to thank the European Commission and its SME Instrument Horizon 2020 program, the Ministry of Science and Innovation through its Collaboration Challenges program, ENISA, and different private investors, such as Ship2B, for having placed their trust in our project.

We continue to work very hard to ensure that all R&D investments have a successful outcome. The recent obtaining of the CE mark as a medical device allows us to start the commercialization of our device soon. So we can say that all the efforts made so far have already seen benefits and that we are about to meet one of our main objectives: to make available to people with epilepsy a solution that improves their quality of life.

For all of this, thank you from the entire mjn-neuro team.

One Comment

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.